The Drugs Controller General of India (DCGI) on Tuesday approved India’s first indigenously developed mRNA vaccine against COVID-19 manufactured by Gennova Biopharmaceuticals for restricted emergency use for those aged 18 years and above, official sources said on Tuesday. While other mRNA vaccines require to be stored at sub-zero temperatures, Gennova’s mRNA vaccine can be stored … Read more
DCGI Approved Corbevax Vaccine for 5 to 12 Years Age Group, Covaxin Vaccine for 6-12 Age Groups: The Drugs Controller General of India (DCGI) has granted restricted emergency use authorisation (EUA) to Covaxin for use in 6 to 12 years old children. The national drug regulator has asked Covaxin manufacturer Bharat Biotech to submit safety data. … Read more
Covid working group of NTAGI will review this week data of Serum Institute of India’s (SII) anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above, official sources said on Wednesday. India’s drug regulator had approved Covovax for restricted use in … Read more
Director, Government and Regulatory Affairs at the SII, Prakash Kumar Singh had put in an application to the DCGI on January 6 stating the Pune-based firm, in collaboration with Novavax Inc, is working on the development of a vaccine against omicron, an official source said, adding that the SII has obtained permission and licence to … Read more
The meeting of the Subject Expert Committee of Central Drug Standards Control Organisation is scheduled to be held today to discuss Dr Reddy’s application seeking emergency use approval for Sputnik V vaccine. Covid-19 vaccine India update: The Subject Expert Committee (SEC) of the Central Drug Standards Control Organisation is likely to meet today to take … Read more
Gennova Biopharmaceutical’s vaccine candidate is the first mRNA-based vaccine to be produced in India. (Representative Image, IE) After Covaxin and Covishield, now Pune-based drugmaker firm, Gennova Biopharmaceuticals is all set to start early to mid-stage human trials of its Covid-19 vaccine, HGCO19. The trials will start ‘’soon’’ and around 620 people will be enrolled for … Read more